Brief: RenovoRx Announces Initial Results In Pharmacokinetic Substudy
18/01/2023 14:07
Jan 18 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ANNOUNCES INITIAL RESULTS IN PHARMACOKINETIC (PK)
SUBSTUDY: DATA ON RENOVOGEM™ SUPPORTS POTENTIAL FOR RENOVOTAMP®
THERAPY PLATFORM TO INCREASE LOCAL GEMCITABINE (CHEMOTHERAPY)
DELIVERY AND DECREASE SIDE EFFECTS OF PANCREATIC CANCER
TREATMENT
Source text for Eikon: ID:nBwbG5Zzta
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies